Literature DB >> 25537656

Evaluation of apparent diffusion coefficient associated with pathological grade of lung carcinoma, before therapy.

Haidong Liu1, Ying Liu1, Tielian Yu1, Ning Ye1, Qing Wang1.   

Abstract

PURPOSE: To investigate the feasibility and utility of apparent diffusion coefficient (ADC) in predicting the tumor cellular density and grades of lung cancers.
MATERIALS AND METHODS: Forty-one consecutive patients (26 men and 15 women; mean age, 59.9 years) with histologically proven lung cancers were enrolled in the study and underwent MR examination. ADC values and tumor cellular density of different histological grades were analyzed. The relationship of the ADC with tumor cellular density and grades were also evaluated.
RESULTS: The ADC values of lung cancer in grade III was significantly lower than those in grade I and grade II (P = 0.008 and 0.011, respectively). The cellular density in grade III was significantly higher than other two grades (P = 0.029 and 0.022, respectively). ADC value of lung cancer correlated negatively with grades and tumor cellular density (P = 0.001 and P = 0.001, respectively). According to the ROC analysis, the cutoff value of ADC was 1.175 × 10(-3) mm(2) /s with the optimal sensitivity (88.2%) and specificity (62.5%), respectively.
CONCLUSION: ADC measurement of lung cancer was a helpful method to evaluate the pathological grade and tumor cellular density. The quantitative analysis of ADC in conjunction with conventional MR findings could provide more valuable information for the assessment of pulmonary tumor. J
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  apparent diffusion coefficient; diffusion-weighted imaging; lung cancer; magnetic resonance imaging; pathological grade

Mesh:

Substances:

Year:  2014        PMID: 25537656     DOI: 10.1002/jmri.24823

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  6 in total

1.  Spin-echo and diffusion-weighted MRI in differentiation between progressive massive fibrosis and lung cancer.

Authors:  Serkan Guneyli; Meltem Tor; Hur Hassoy; Murat Serhat Aygun; Emre Altinmakas; Susamber Dik Altintas; Recep Savas
Journal:  Diagn Interv Radiol       Date:  2021-07       Impact factor: 2.630

2.  Non-small cell lung cancer: Whole-lesion histogram analysis of the apparent diffusion coefficient for assessment of tumor grade, lymphovascular invasion and pleural invasion.

Authors:  Naoko Tsuchiya; Mariko Doai; Katsuo Usuda; Hidetaka Uramoto; Hisao Tonami
Journal:  PLoS One       Date:  2017-02-16       Impact factor: 3.240

3.  Diffusion-weighted MRI in solitary pulmonary lesions: associations between apparent diffusion coefficient and multiple histopathological parameters.

Authors:  Feng Zhang; Zien Zhou; Daoqiang Tang; Danni Zheng; Jiejun Cheng; Liaoyi Lin; Jianrong Xu; Xiaojing Zhao; Huawei Wu
Journal:  Sci Rep       Date:  2018-07-26       Impact factor: 4.379

4.  The value of diffusion kurtosis imaging, diffusion weighted imaging and 18F-FDG PET for differentiating benign and malignant solitary pulmonary lesions and predicting pathological grading.

Authors:  Ziqiang Li; Yu Luo; Han Jiang; Nan Meng; Zhun Huang; Pengyang Feng; Ting Fang; Fangfang Fu; Xiaochen Li; Yan Bai; Wei Wei; Yang Yang; Jianmin Yuan; Jianjian Cheng; Meiyun Wang
Journal:  Front Oncol       Date:  2022-07-29       Impact factor: 5.738

5.  Identification of Potential MR-Derived Biomarkers for Tumor Tissue Response to 177Lu-Octreotate Therapy in an Animal Model of Small Intestine Neuroendocrine Tumor.

Authors:  Mikael Montelius; Johan Spetz; Oscar Jalnefjord; Evelin Berger; Ola Nilsson; Maria Ljungberg; Eva Forssell-Aronsson
Journal:  Transl Oncol       Date:  2018-01-11       Impact factor: 4.243

6.  Optimizing diffusion-weighted magnetic resonance imaging for evaluation of lung tumors: A comparison of respiratory triggered and free breathing techniques.

Authors:  Signe Swerkersson; Oscar Grundberg; Karl Kölbeck; Andreas Carlberg; Sven Nyrén; Mikael Skorpil
Journal:  Eur J Radiol Open       Date:  2018-11-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.